On 25th April, 2018, “The Most Attractive Hong Kong Stock Connect Companies for Institutional Investors” Award Ceremony was grandly held in Shenzhen Marco Polo Hotel. Attributed to its steadily growing performance and its innovation-oriented development direction, China Medical System Holdings Limited (“CMS”), as a premium underlying stock of Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connects, has received continuous recognition and attention from investors gradually. CMS was successfully selected as “The Most Attractive Hong Kong Stock Connect Companies for Institutional Investors”.
The successive opening of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect has allowed mainland investors to participate in the Hong Kong stock market through the interconnection mechanism. With further increase of the activity level of the Hong Kong stock market, the premium Hong Kong underlying stocks have gradually entered into the vision of investors. The first “Most Attractive Hong Kong Stock Connect Companies for Institutional Investors” Award is co-organized by the Yuediaoyan platform and Gelonghui, and it is also supported by the Hong Kong Stock Exchange and Euroland IR. The winners were voted by more than 30,000 domestic and oversea institutional investors and analysts. And they were selected to represent the premium Hong Kong listed companies with investment value and growth potential, which have attracted the attention and recognition from the capital market.
With the opening of Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, the capital market has paid more attention to CMS gradually, especially the mainland capital market. We sincerely appreciate the supports and affirmation from domestic and oversea investors and analysts. In the future, CMS will steadily improve its operating performance, while constantly maintaining the close communication with its overseas investors. In addition, CMS will continue to improve the communication with mainland investors via various channels, building up mutual understanding, and strives to become a leading pharmaceutical company in the capital market. CMS expects to witness the company’s future development together with both domestic and oversea investors.
